U.S. pharmaceutical giant announces outlook for vaccine `` earlier next year '' March 31 8:22
Johnson & Johnson, a major US pharmaceutical company, has announced that it will be able to complete a vaccine against the new coronavirus early next year and provide enough dose for approximately one billion doses.
No new coronavirus has so far been found to be effective, and there are no vaccines to prevent it. Working on the development of
U.S. pharmaceutical giant Johnson & Johnson has announced on Tuesday its outlook for vaccine development will be "complete early next year".
According to the announcement, vaccine candidate substances have already been narrowed down, and clinical trials on humans will begin in September at the latest, at the latest, to confirm safety and efficacy.
Earlier next year, it was approved by the US Food and Drug Administration (FDA) and is expected to be available worldwide.
It also means that the production system can be expanded to produce an amount that can be inoculated for one billion doses at an early stage.
Regarding vaccines, the NIH (National Institutes of Health) and private companies have begun clinical trials of vaccines under development from this month, and pharmaceutical venture companies and research institutes around the world are rushing to develop new coronavirus infections. There are growing expectations around the world as a trump card to end the process.